Aslan Fred

Track

Insider profile

Performance

Overall performance
Performance over holding periods
30 days 90 days 120 days
Average return -9% 8.2% 15.1%
Success rate 0% 68% 82%
Transactions
1 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Aslan Fred's trades of Artiva Biotherapeutics Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-19 2026-05-19
S Sale
84,896 +11.7%
342.38
US$2,037,363 		84,896 +11.7% 342.38 US$2,037,363
2026-05-18 2026-05-18
PrS Proposed sale
40,795
368.82
US$1,515,426 		40,795 368.82 US$1,515,426
2025-12-15 2025-12-15
PrS Proposed sale
79,205
125.17
US$2,132,165 		79,205 125.17 US$2,132,165
2025-12-15 2025-12-15
PlS Planned sale
3,187 -0.3%
6.00
US$19,122 		3,187 -0.3% 6.00 US$19,122
2025-11-17 2025-11-17
PrS Proposed sale
6,375
3.25
US$20,719 		6,375 3.25 US$20,719
2025-11-17 2025-11-17
PlS Planned sale
6,375 -1.8%
3.38
US$21,522 		6,375 -1.8% 3.38 US$21,522
2025-10-17 2025-10-17
PrS Proposed sale
25,500
2.77
US$70,635 		25,500 2.77 US$70,635
2025-10-17 2025-10-17
PlS Planned sale
25,500 -6.7%
6.00
US$153,000 		25,500 -6.7% 6.00 US$153,000
2025-08-18 2025-08-15
PlS Planned sale
25,500 -6.2%
2.73
US$69,579 		25,500 -6.2% 2.73 US$69,579
2025-08-15 2025-08-15
PrS Proposed sale
25,500
2.70
US$68,850 		25,500 2.70 US$68,850